Floatz Rating
B59/100
Confidence
Indicative
Sponsor
Macquarie University, Australia
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
52High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06658977CT.gov RolloverTreatment With Triumeq for People With ALS Following the Lighthouse II Trial | — | Terminated | — | — | — |
NCT05193994CT.gov Triumeq in Amyotrophic Lateral Sclerosis | — | Terminated | — | — | — |
NCT02437110CT.gov HERV-K Suppression Using Antiretroviral Therapy in Volunteers With Amyotrophic Lateral Sclerosis (ALS) | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Amyotrophic Lateral Sclerosis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Dolutegravir (this asset) | Macquarie University, Australia | P3 | B · 59 |
| Taurursodiol | Amylyx Pharmaceuticals Inc. | P3 | BBB |
| Tofersen | Biogen | P4 | BBB |
| Mexiletine | Bjorn Oskarsson, MD | P4 | BB |
| Riluzole | AB Science | P4 | BB |
| Diacetyl(N(4)-Methylthiosemicarbazonato) Copper (Ii) | Collaborative Medicinal Development Pty Limited | P2/3 | BB |
| Mci-186 | Tanabe Pharma Corporation | P3 | BB |
| mt-1186 | Tanabe Pharma Corporation | P3 | BB |
| Kns-760704 | Knopp Biosciences | P3 | BB |
+42 more in the Amyotrophic Lateral Sclerosis cohort
Other indications for Dolutegravir
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| HIV Infectious Disease | — | P4 | BBB · 76 |
| Lipodystrophy | — | P4 | BBB · 73 |
| Congenital Heart Disease | — | P4 | BB · 69 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Dolutegravir in Amyotrophic Lateral Sclerosis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/dolutegravir-amyotrophic-lateral-sclerosis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →